Completion of shortfall bookbuild and $21.3m capital raise

PACIFIC EDGE COMPLETES SHORTFALL BOOKBUILD AND $21.3 MILLION CAPITAL RAISING
13 November 2017

Pacific Edge Limited (NZX: PEB) (Pacific Edge) advises that it has completed the shortfall bookbuild component of
its $21.3 million capital raise announced on 11 October 2017 (Offer), with support from both institutional and
other eligible shareholders. All of the shares available under the Offer have now been taken up.

The clearing price under the Shortfall Bookbuild was NZ$0.32 per share.

Chair of Pacific Edge, Chris Gallaher, said: “We are pleased to have raised the full NZ$21.3m to help fund our
continued growth as we target getting Pacific Edge to a cashflow breakeven position as soon as possible.”

The new shares taken up under the Offer are expected to be allotted and commence trading on the NZX Main
Board on Wednesday 15 November 2017.

- ENDS -

David Darling
Chief Executive Officer
Pacific Edge Ltd

Cell: +64 21 797 981
Ph: +64 3 479 5800

OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and
commercialisation of diagnostic and prognostic tests for better detection and management of cancer. The company is
developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central
laboratories in New Zealand and the USA. The company’s products have been tested and validated in international multi-
centre clinical studies.

Pacific Edge has three proprietary, novel, accurate, molecular diagnostic products in-market providing actionable results, and
better detection and management of urothelial cancer. Cxbladder Detect and Cxbladder Triage are available through the
company’s dedicated CLIA certified laboratories for customers in New Zealand, Australia and the USA. Cxbladder Monitor
launched in New Zealand in December 2015 and is anticipated being available in the US in 2016.

ABOUT Cxbladder Triage www.cxbladder.com
Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to
accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more
extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of
patients with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a
low probability of having urothelial carcinoma.

ABOUT Cxbladder Detect www.cxbladder.com
Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a
patients’ urine. Cxbladder Detect was launched in 2013 in the USA and is commercially available in New Zealand, Australia
and the USA as a Laboratory Developed Test (LDT) from the company’s CLIA certified laboratories. Cxbladder Detect provides
clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective adjunct to
cystoscopy.

ABOUT Cxbladder Monitor www.cxbladder.com
Cxbladder Monitor, the third test in the Cxbladder portfolio for urologists, is a proprietary, non-invasive, molecular diagnostic
test that combines genomic biomarkers measured from a small quantity of a patient’s urine, with patient specific clinical
factors to better monitor bladder cancer patients for recurrence. Bladder cancer has a recurrence rate of 50-80% and
requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior history of urothelial cancer (UC)
whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial carcinoma. Cxbladder Monitor
is designed to be used as the preferred adjunct test to cystoscopy in the management of patients for ongoing evaluation of
recurrent bladder cancer.

ABOUT Cxbladder Resolve www.cxbladder.com
Cxbladder Resolve is a proprietary, non-invasive, molecular diagnostic test that combines genomic biomarkers measured
from a small quantity of a patient’s urine, with patient characteristics for the identification of patients who are likely to have
aggressive or more advanced bladder cancer. Cxbladder Resolve, when used as part of the primary evaluation of haematuria
and/or in conjunction with other Cxbladder tests (Triage, Detect), is designed to assist clinicians by accurately identifying
patients with a high probability of having high grade or late stage bladder cancer, for whom alternative or expedited
treatment options may be warranted, or who can be prioritised for further investigation in high throughput settings.

Refer to www.cxbladder.com for more information.